Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
Location: Home > Pharma China Web Edition > Product/R&D News    
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
WiCON International Group
311 Sayre Drive,
Princeton, NJ 08540, USA
Tel/Fax: +1 702-9953905
Email:
info@pharmachinaonline.com

China Head Office
c/o Beijing Jicai PharmTech
Suite B-17D, Oriental Kenzo Plaza
48 Dongzhimenwai Dajie
Dongcheng District
Beijing 100027, China
Tel: +86 10 84476010
Fax: +86 10 84476010
Email:
info@pharmachinaonline.com
 
 
 
Product/R&D News
 
Review of Chinese Drug Clinical Trials on the Official Registrati... 12/20/2017
BeiGene Initiates Pivotal Trial of PARP Inhibitor Pamiparib for O... 12/19/2017
CFDA Accepts Innovent Biologics' NDA for PD-1 Candidate IBI308 12/14/2017
Shanghai Establishes Regional Ethics Committee for Clinical Resea... 12/13/2017
CFDA Approves Genscript's Clinical Trial Application for CAR-T Bl... 12/11/2017
BeyondSpring Initiates Global Phase 2/3 Trial of Plinabulinin Chi... 12/5/2017
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in ... 11/29/2017
China Approves Use of Recombinant Interferon against Avian Flu in... 11/24/2017
CFDA Approves Clinical Trial of Chinese-developed 2nd Generation ... 11/23/2017
Ascentage Announces U.S. FDA Acceptance of Its IND for Novel IAP ... (free) 11/15/2017
RiboQuark Enrolls First Patient in China for a Global Pivotal Tri... 11/13/2017
Page:4/4    Total number of articles:101  :[1][2][3][4]

 
 
 
 
© Wicon International Group  Support by: www.heightow.com   Site map | Contact Us | Links